G35
Conditions
Interventions
Group 1: A) Concentrations of biomarkers are determined in patients with contrast enhancing lesions in the MRI.
Group 2: B) Concentrations of biomarkers are determined in patients without contrast enh
Sponsors
Klinikum der Johann Wolfgang Goethe-Universität Zentrum der Neurologie und Neurochirurgie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Planned implementation of a contrast enhanced cerebral or spinal MRI in patients with multiple sclerosis (including clinically isolated syndrome and radiologically isolated syndrome)
Exclusion criteria
Exclusion criteria: Age of patient < 18 years, other current present neurological diseases such as stroke, dementia, M. Parkinson or similar.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The diagnostic accuracy of the S100B biomarker-test, determined through an ROC-analysis ("area under the curve" (AUC), sensitivity, specificity, positive and negative predictive value), which means the respective serum concentration, which separates patients with contrast enhancing lesions and without. The Parameter is measured in a time span of 5 days before or after the MRI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary criteria are further biomarkers (GFAP, MMP-9, Endothelin) in a time span of 5 days before or after the MRI. | — |
Countries
Germany
Contacts
Public ContactChristian Förch
Klinikum der Johann Wolfgang Goethe-Universität Zentrum der Neurologie und Neurochirurgie
Outcome results
None listed